论文部分内容阅读
目的:评价注射用人免疫球蛋白对小儿川崎病患者的临床疗效及不良反应。方法:选取2013年1月—2014年4月收治的川崎病患儿80例,将其分为观察组和对照组;对照组患者给予阿司匹林治疗,观察组患者在对照组治疗基础上给注射用人免疫球蛋白治疗,比较两组患者治疗后的临床疗效及不良反应的发生情况。结果:观察组患者治疗的总有效率为97.50%显著高于对照组为85.00%(P<0.05);其不良反应的发生率为20.00%明显高于对照组为2.50%(P<0.05)。结论:注射用人免疫球蛋白用于治疗小儿川崎病患者的临床疗效较为显著,但可导致患儿发生高热、寒战、皮疹、胸闷、头痛等不良反应,影响其疗果,临床用药过程中应密切观察患儿不良反应的发生情况,以确保用药安全。
Objective: To evaluate the clinical efficacy and adverse reactions of injection of human immunoglobulin in children with Kawasaki disease. Methods: Eighty children with Kawasaki disease who were admitted from January 2013 to April 2014 were divided into observation group and control group. Patients in control group were treated with aspirin. Patients in observation group were injected with human Immunoglobulin therapy, the clinical efficacy of the two groups were compared after treatment and the incidence of adverse reactions. Results: The total effective rate of the observation group was 97.50%, which was significantly higher than that of the control group (85.00%, P <0.05). The incidence of adverse reactions in the observation group was 20.00%, significantly higher than that in the control group (2.50%, P <0.05). Conclusion: The clinical efficacy of injecting human immunoglobulin for the treatment of pediatric children with Kawasaki disease is more significant, but it can cause adverse reactions such as fever, chills, rash, chest tightness and headache in children, which may affect its outcome and should be closely related to clinical medication Observe the occurrence of adverse reactions in children to ensure drug safety.